Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Encapsulation drug microsphere of medicament-eluting coronary artery stent and method for preparing same

A technology of drugs and microspheres, applied in the medical field of treating cardiovascular diseases, can solve the problems of obstructing the vascular endothelialization on the surface of stents, LAST and stent malapposition, high sensitization and inflammatory reaction, and achieve excellent biocompatibility, Reduce the phenomenon of blasting and release, which is beneficial to the effect of crawling

Inactive Publication Date: 2009-08-26
D PULSE MEDICAL BEIJING CO LTD
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This solution generally has the following problems in use: 1. The DES coated with polymer layer has poor biocompatibility, and it is easy to generate thrombus in the blood vessel for a long time; 2. It is only on the surface of the stent matrix With a polymer layer, it is difficult to slowly release the drug over a long period of time, and the stent matrix (or stent matrix with a polymer layer) after the drug is released will hinder the endothelialization of blood vessels on the surface of the stent, thereby 3. The polymer layer loaded with drugs can also cause hypersensitivity and inflammatory reactions; etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Encapsulation drug microsphere of medicament-eluting coronary artery stent and method for preparing same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] 300 mg of drug rapamycin (Rapamycin) (dissolved in acetone to form a 10% rapamycin acetone (Acetone) solution) was injected into 300 ml of chitosan acidic aqueous solution. The percentage by weight of each substance in the solution is 3% of chitosan; 2% of acetic acid; 2% of sodium chloride; and 93% of distilled water. (wherein chitosan is a drug microsphere encapsulation material, aqueous acetic acid is a solvent for chitosan, and sodium chloride plays a role in promoting the dissolution of chitosan better), so that the obtained

[0048] medicine / chitosan= A solution (where the A value is between 12%-18%, including two critical values).

[0049] The chitosan acidic aqueous solution was mixed with 3-5 ml of liquid paraffin / ether mixture containing 0.85 g of emulsifier—Sorbitan Sesquioleate (Sorbitan Sesquioleate, Arlacel 83). This mixed liquor is the solvent of emulsifier, and its component weight ratio is

[0050] Liquid paraffin / ether=35 ml / 25 ml.

[0051] The liq...

Embodiment 2

[0056] Drug rapamycin (Rapamycin) 200 mg (dissolved in acetone to form 1% rapamycin acetone (Acetone) solution) was injected into 250 ml chitosan acidic aqueous solution. The percentage by weight of each substance in the acidic solution is 2% chitosan; 1% acetic acid; 97% distilled water. (wherein chitosan is a drug microsphere encapsulation material, and the aqueous acetic acid solution is a solvent for chitosan), so that obtaining

[0057] medicine / chitosan= A solution (A value is between 13% and 17%).

[0058] Set the mass concentration to B(B value is between 0.45 mg-1.0 mg / ml) sodium tripolyphosphate (TPP) aqueous solution is slowly added dropwise to the above-mentioned drug-containing chitosan acetic acid solution under the high-speed stirring of 2000 rpm, and The mass concentration of chitosan in the solution was C (C value is between 0.5 milligram-1.0 milligram / ml), and the quantity of dropping is that the mass ratio of medicine-containing chitosan acetic acid solu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
Login to View More

Abstract

The invention relates to a method for preparing encapsulation medicament microspheres of a medicament-eluting coronary artery stent, which comprises the following steps: a, providing a special medicament for the medicament-eluting coronary artery stent, and dissolving the special medicament in a solvent to form a medicament solution; b, providing a capsule wall material, and dissolving the same in a solvent to form a capsule wall material solution; c, sufficiently stirring the medicament solution and the capsule wall material solution evenly to form a mixed solution of the medicament and the capsule wall material, and obtaining the microspheres through high-speed stirring and ultrasonic emulsification; and d, centrifugalizing the microspheres, washing the microspheres to a neutral state with distilled water, and drying the microspheres to obtain the encapsulation medicament microspheres. With the method, the encapsulation medicament microspheres of the medicament-eluting coronary artery stent is obtained, and the sphericized encapsulation medicament microspheres comprise natural polysaccharide and polysaccharide biomaterials so as to avoid a plurality of shortages in the prior art.

Description

technical field [0001] The invention relates to medical technology for treating cardiovascular diseases, in particular to a drug-eluting coronary stent (DES) encapsulated drug microsphere and a preparation method thereof. Background technique [0002] Drug-eluting coronary stents, referred to as drug-eluting stents, have been widely used clinically, and the results show that their curative effect in the treatment of coronary heart disease (coronary stenosis) is definite, and it can significantly reduce intimal hyperplasia and late stage after stenting. Loss of coronary lumen, thereby reducing intra-segment coronary restenosis and target lesion revascularization rate (TLR), which ultimately reduces the incidence of severe and adverse events (MACE), making it the current treatment for coronary artery disease at home and abroad. Stenosis is one of the main means of coronary artery disease. However, with the widespread application of DES, the safety of DES, especially late late...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61L31/16A61F2/82
Inventor 郑兴仪王征吕向东
Owner D PULSE MEDICAL BEIJING CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com